Physician profile
David E Pawlowski
NPI 1962485318
$3,880.57
in general payments reported to CMS, 2019-2025
34 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $401 · 2021: $738 · 2022: $749 · 2023: $912 · 2024: $470 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,651 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,651.41 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $682.63 | 2019-2025 | Rybelsus, Wegovy, Ozempic |
| Lilly USA, LLC | $596.43 | 2019-2024 | Jardiance, Mounjaro, Emgality |
| Pfizer INC. | $415.67 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.46 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $208.30 | 2023-2024 | Farxiga, Breztri, Fasenra |
| Abbvie INC. | $168.19 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $140.50 | 2021-2022 | |
| Amgen INC. | $134.09 | 2021-2024 | Otezla, Repatha, Prolia |
| Merck Sharp & Dohme LLC | $125.11 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Glaxosmithkline, LLC. | $98.08 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $92.79 | 2022-2023 | |
| Astellas Pharma US INC | $91.20 | 2019-2024 | Veozah |
| Amarin Pharma, INC. | $89.79 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.88 | 2023-2024 | Trintellix, Gattex |
| Lundbeck LLC | $78.75 | 2023-2024 | Rexulti |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $77.03 | 2022-2024 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $57.54 | 2022 | |
| Sumitomo Pharma America, INC. | $50.09 | 2024-2025 | Gemtesa |
| Sanofi Pasteur INC. | $49.03 | 2019-2022 | |
| Esperion Therapeutics, INC. | $47.82 | 2023-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $46.90 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $43.39 | 2023 | Nuedexta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.24 | 2023-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $29.75 | 2023 | Camzyos, Eliquis |
| Kowa Pharmaceuticals America, INC. | $23.63 | 2021 | |
| Idorsia Pharmaceuticals US INC | $20.35 | 2023 | Quviviq |
| Horizon Therapeutics Plc | $19.17 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.75 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $18.51 | 2021 | |
| Genentech USA, INC. | $18.04 | 2021 | |
| Exact Sciences Corporation | $17.21 | 2023 | Cologuard Collection Kit |
| Ferring Pharmaceuticals INC. | $16.49 | 2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $15.07 | 2023 | |
| Eisai INC. | $14.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pawlowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.